Morgan Tapped to Lead Company’s Mission to Disrupt Drug Discovery and Precision Medicine
Zephyr AI, Inc. (“Zephyr AI”), a high-growth healthcare technology company, has appointed David L. Morgan Chief Executive Officer (CEO). Utilizing disparate data, Zephyr AI applies layered machine learning and transparent algorithms to generate actionable insights and inform multidimensional prediction models. The Company is making advances in precision medicine and drug discovery by revealing novel therapeutics, identifying new indications for existing therapeutics, matching biomarkers to treatments, repurposing orphan drugs, and uncovering synergistic therapeutic combinations. Mr. Morgan succeeds Zephyr AI’s Co-founder, Dr. Yisroel Brumer, who assumes the role of Executive Vice Chairman.
Recommended AI News: Public Service Company of Oklahoma Selects ICF for Energy Efficiency Contract
“I have been in awe of Zephyr AI’s breakthrough accomplishments over the past year, and am fortunate to work on this once-in-a-lifetime opportunity”
“We live in a modern world, but very little about our current healthcare system is innovative,” said Grant Verstandig, Executive Chairman of Zephyr AI’s Board of Directors. “Zephyr AI believes that machine learning is a necessary component for the future, offering an ability to improve our struggling system in significant ways, by driving down the cost of important trials, easing burdens for doctors, and quickly bringing personalized healthcare information directly to the patient. This disruption will effectively lead to better outcomes for the patient, the provider and the community. David – with his years of invaluable experience – will help take us there.”
Mr. Morgan has a 20-year track record of transformative leadership in healthcare, health technology, and biopharmaceutical companies. He has successfully led numerous mergers and acquisitions that resulted in rapid growth within the business sectors of oncology, transplantation, in vitro diagnostics, and clinical trials. Mr. Morgan previously served as the President of Eurofins Transplant Diagnostics US and Senior Vice President of Eurofins Scientific Group where he managed a portfolio of subsidiary companies.
Recommended AI News: Bardasz Announces New Website Launch
“David is uniquely qualified to lead our company through the next phase of its evolution and growth,” said Dr. Brumer. “He will scale the team, technology, and scientific infrastructure to support our rapidly growing research pipeline and ambitious company milestones.”
“I have been in awe of Zephyr AI’s breakthrough accomplishments over the past year, and am fortunate to work on this once-in-a-lifetime opportunity,” Mr. Morgan said. “I look forward to building commercial partnerships with industry leaders to help them solve some of health care’s most pressing problems.”
Mr. Morgan joins the company with an established board, including Dr. Sol J. Barer, Co-founder & former CEO, Celgene Corporation, Dr. Jack Rowe, former CEO, Aetna, Ken Samet, President and CEO, MedStar Health, and Mr. Verstandig, founder and Chairman of Red Cell Partners.
Mr. Morgan will also join Red Cell Partners, an investment and incubation firm that backs, builds, and scales early stage technology-led companies in the healthcare and national security sectors, as an Operating Partner in their healthcare practice. Zephyr AI was founded and incubated by Red Cell Partners and Red Cell Partners remains the majority investor in Zephyr AI.
Recommended AI News: iHeartMedia Utilizes Veritone’s Synthetic Voice to Produce Podcasts for New Markets
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.